• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在比较药代动力学研究中对不同药物吸收速率间接测量方法的评估。

Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.

作者信息

Lacey L F, Keene O N, Duquesnoy C, Bye A

机构信息

Department of Clinical Pharmacokinetics, Glaxo Group Research Ltd., Greenford, Middlesex, U.K.

出版信息

J Pharm Sci. 1994 Feb;83(2):212-5. doi: 10.1002/jps.2600830219.

DOI:10.1002/jps.2600830219
PMID:8169791
Abstract

As indirect measures of rate of drug absorption (metrics), maximum plasma concentration (Cmax) is confounded by extent of drug absorption and the time to reach Cmax (tmax) is a discrete variable, dependent on blood sampling frequency. Building on the work of Endrenyi et al., we have compared different metrics, including Cmax/area under the curve of concentration versus time from time zero to infinity (AUC infinity), partial AUC from zero to tmax (AUCp), and Cmax.tmax with simulated experiments. Importantly, the performance of these metrics was assessed with the results of actual pharmacokinetic studies involving Glaxo drugs. The results of the simulated and real experiments were consistent and produced the following unambiguous findings: (1) Cmax/AUC infinity is a more powerful metric than Cmax in establishing bioequivalence when the formulations are truly bioequivalent; (2) Cmax/AUC infinity is more sensitive than Cmax at detecting differences in rate of absorption when they exist; and (3) the treatment ratios for AUCp, AUCp/AUC infinity, and Cmax.tmax are very imprecisely estimated and are of no practical value as measures of rate of absorption. Of the metrics examined, Cmax/AUC infinity is the most sensitive and powerful indirect measure of rate of drug absorption in comparative pharmacokinetic studies involving immediate-release dosage forms and should be used instead of Cmax in bioequivalence testing.

摘要

作为药物吸收速率的间接测量指标,最大血药浓度(Cmax)受药物吸收程度的影响,而达到Cmax的时间(tmax)是一个离散变量,取决于血样采集频率。基于恩德雷尼等人的研究成果,我们通过模拟实验比较了不同的指标,包括Cmax与零至无穷大时间的浓度-时间曲线下面积(AUC infinity)、零至tmax的部分AUC(AUCp)以及Cmax·tmax。重要的是,这些指标的性能通过涉及葛兰素药物的实际药代动力学研究结果进行了评估。模拟实验和实际实验的结果一致,并得出了以下明确的结论:(1)当制剂真正生物等效时,Cmax/AUC infinity在确立生物等效性方面比Cmax更具效力;(2)当存在吸收速率差异时,Cmax/AUC infinity比Cmax更敏感地检测到这些差异;(3)AUCp、AUCp/AUC infinity和Cmax·tmax的治疗比值估计非常不准确,作为吸收速率的测量指标没有实际价值。在所研究的指标中,Cmax/AUC infinity是涉及速释剂型的比较药代动力学研究中最敏感且最具效力的药物吸收速率间接测量指标,在生物等效性测试中应使用该指标而非Cmax。

相似文献

1
Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.在比较药代动力学研究中对不同药物吸收速率间接测量方法的评估。
J Pharm Sci. 1994 Feb;83(2):212-5. doi: 10.1002/jps.2600830219.
2
Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies.在比较药代动力学研究中,评估不同的部分曲线下面积作为药物吸收速率的间接测量指标。
Eur J Pharm Sci. 1998 Oct;6(4):259-64. doi: 10.1016/s0928-0987(97)10023-9.
3
Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.随机试验中口服溶液与普通片的双氯芬酸钾的药代动力学差异:进食与禁食状态的影响。
Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.
4
Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state.评估不同指标作为稳态下缓释剂型药物吸收速率的间接测量方法。
Pharm Res. 1995 Jan;12(1):103-7. doi: 10.1023/a:1016246922519.
5
Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.用于速释药物制剂吸收速率比较的特性选择及其生物等效性范围
Int J Clin Pharmacol Ther. 1994 Jul;32(7):323-8.
6
Partial-area method in bioequivalence assessment: naproxen.生物等效性评估中的局部面积法:萘普生
Biopharm Drug Dispos. 1997 Mar;18(2):103-16. doi: 10.1002/(sici)1099-081x(199703)18:2<103::aid-bdd4>3.0.co;2-s.
7
Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.评估缓释产品体内性能的标准:在硝苯地平制剂中的应用。
J Pharm Sci. 1995 Oct;84(10):1160-3. doi: 10.1002/jps.2600841005.
8
Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.生物等效性研究中吸收速率经验指标的敏感性。
Pharm Res. 2000 May;17(5):583-8. doi: 10.1023/a:1007521016985.
9
Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate.为何单剂量生物等效性研究中的吸收速率推断往往并不恰当。
Pharm Res. 1998 Feb;15(2):276-9. doi: 10.1023/a:1011974803996.
10
Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.使用临床试验模拟评估高变异药物的生物等效性。II:使用AUC和Cmax比较单剂量和多剂量试验。
Pharm Res. 1998 Jan;15(1):98-104. doi: 10.1023/a:1011961006297.

引用本文的文献

1
A Vector Theory of Assessing Clinical Trials: An Application to Bioequivalence.一种评估临床试验的向量理论:在生物等效性中的应用。
J Cardiovasc Dev Dis. 2024 Jun 21;11(7):185. doi: 10.3390/jcdd11070185.
2
Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.有限吸收时间(F.A.T.)概念在生物等效性评估中的应用。
Pharm Res. 2024 Jul;41(7):1413-1425. doi: 10.1007/s11095-024-03727-w. Epub 2024 Jun 19.
3
The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant.
首个以α-生育酚为佐剂的口服疫苗的基于生理的药代动力学(PBPK)模型。
Pharmaceutics. 2023 Sep 13;15(9):2313. doi: 10.3390/pharmaceutics15092313.
4
An In Silico Approach toward the Appropriate Absorption Rate Metric in Bioequivalence.生物等效性中合适吸收速率指标的计算机模拟方法。
Pharmaceuticals (Basel). 2023 May 10;16(5):725. doi: 10.3390/ph16050725.
5
The Two Main Goals of Bioequivalence Studies.生物等效性研究的两个主要目标。
AAPS J. 2017 Jul;19(4):885-890. doi: 10.1208/s12248-017-0048-x. Epub 2017 Feb 2.
6
Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics.提议使用部分曲线下面积作为辅助指标,以确定长效注射用抗精神病药物三角肌注射与臀肌注射之间的生物等效性。
Eur J Drug Metab Pharmacokinet. 2016 Dec;41(6):659-664. doi: 10.1007/s13318-016-0348-z.
7
Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.应用部分 AUC(PAUC)评估生物等效性——以复杂吸收为特征的案例研究:哌醋甲酯。
Pharm Res. 2013 Jan;30(1):191-202. doi: 10.1007/s11095-012-0862-x. Epub 2012 Sep 25.
8
An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine.一种用于预测空腹上小肠中高渗透性亲脂性弱碱的腔内浓度和沉淀的体外方法。
Pharm Res. 2012 Dec;29(12):3486-98. doi: 10.1007/s11095-012-0844-z. Epub 2012 Aug 14.
9
Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.采用标化平均生物等效性评估高变异药物的生物等效性。
Clin Pharmacokinet. 2009;48(11):725-43. doi: 10.2165/11318040-000000000-00000.
10
Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.偏头痛患者口服舒马曲坦的药代动力学及临床反应的个体间差异。
Eur J Clin Pharmacol. 2008 May;64(5):489-95. doi: 10.1007/s00228-007-0443-9. Epub 2008 Jan 8.